07:53 AM EDT, 06/20/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Thursday said it has dosed the first patient in the new GOBLET study cohort evaluating a pelareorep combination therapy involving modified FOLFIRINOX (mFOLFIRINOX) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.

The therapy being assessed in this cohort may include the cancer immunotherapy treatment atezolizumab, Oncolytics said. Primary endpoints are objective response rate (ORR) and safety,

The study, which is s supported by a US$5 million Pancreatic Cancer Action Network (PanCAN) grant, is being conducted with a clinical trial group within the German Cancer Society.

The mFOLFIRINOX cohort of the GOBLET study could result in a second pancreatic cancer registration program for the company, Oncolytics chief medical officer Thomas Heineman said.